Testosterone and Prostate Cancer: Latest Concepts and Advances

Abraham Morgentaler, MD, FACS

Associate Professor, Harvard Medical School; Staff, Beth Israel Deaconess Medical Center

For decades the greatest obstacle preventing wide adoption of testosterone therapy was the fear that it would cause aggressive prostate cancer or cause rapid prostate cancer progression. This lecture will review the origins of this erroneous belief and review the latest evidence, including results of testosterone therapy in men who have undergone prior treatment for prostate cancer with surgery or radiation, and in men on active surveil-lance. The limited data regarding testosterone therapy in men with more advanced disease will be reviewed as well. Guidance will be provided for attendees as to when it may be safe to offer testosterone therapy to men at risk for prostate cancer, or with a history of prostate cancer.